L-365260
CAS 118101-09-0 MFCD18101090
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Cholecystokinnin - Receptor Antagonists, GPCR Modulators, GPCR Proteins, Modulators and Antibodies, L, Membrane Protein Biology Tools, Merck & Co., Inc., Kenilworth,NJ, 生化试剂, 生物活性小分子, 细胞生物学, 蛋白质及衍生物
相关文献及参考
- [2]. Chung L, et, al. Cholecystokinin action on layer 6b neurons in somatosensory cortex. Brain Res. 2009 Jul 28;1282:10-9.
- [3]. Dourish CT, et, al. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol. 1990 Jan 25;176(1):35-44.
- [1]. Lotti VJ, et, al. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol. 1989 Mar 21;162(2):273-80.
- [1]. Lotti VJ, et, al. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol. 1989 Mar 21;162(2):273-80.
- [2]. Chung L, et, al. Cholecystokinin action on layer 6b neurons in somatosensory cortex. Brain Res. 2009 Jul 28;1282:10-9.
- [3]. Dourish CT, et, al. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in